Perspective Therapeutics Inc (CATX)
1.60
+0.07
(+4.58%)
USD |
NYAM |
May 17, 16:00
1.595
0.00 (0.00%)
Pre-Market: 20:00
Perspective Therapeutics Research and Development Expense (Annual): 21.31M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 21.31M |
| December 31, 2022 | 1.301M |
| June 30, 2022 | 2.582M |
| June 30, 2021 | 1.427M |
| June 30, 2020 | 1.126M |
| June 30, 2019 | 1.474M |
| June 30, 2018 | 1.746M |
| June 30, 2017 | 0.965M |
| June 30, 2016 | 0.528M |
| June 30, 2015 | 0.615M |
| Date | Value |
|---|---|
| June 30, 2014 | 0.6688M |
| June 30, 2013 | 0.6271M |
| June 30, 2012 | 0.7306M |
| June 30, 2011 | 0.4653M |
| June 30, 2010 | 0.341M |
| June 30, 2009 | 0.9587M |
| June 30, 2008 | 1.358M |
| June 30, 2007 | 1.345M |
| June 30, 2006 | 0.4504M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.126M
Minimum
2020
21.31M
Maximum
2023
4.870M
Average
1.450M
Median
Research and Development Expense (Annual) Benchmarks
| icad Inc | 5.161M |
| Predictive Oncology Inc | -- |
| Xtant Medical Holdings Inc | 1.336M |
| Asensus Surgical Inc | 37.02M |
| Catheter Precision Inc | 0.475M |